Aesthetic Plastic Surgery

, Volume 32, Issue 5, pp 715–722 | Cite as

Novel Topical BoNTA (CosmeTox, Toxin Type A) Cream Used to Treat Hyperfunctional Wrinkles of the Face, Mouth, and Neck

Original Article

Abstract

Background

This study aimed to compare the effect of the stabilized novel topical botulinum neurotoxin type A (BoNTA) cream (CosmeTox) and a placebo cream on subjects, to compare clinician-reported outcomes, and to assess the safety and utility of the novel topical BoNTA cream for treating the entire upper face, chin, and neck areas.

Methods

This study randomized 40 female subjects to receive either topical BoNTA (CosmeTox) cream (2 U/ml) or an identical placebo cream (without BoNTA) on the face, chin, and neck areas. The subjects were followed for 12 weeks. The main outcome measures were the Facial Line Outcomes questionnaire scores and results from the Self-Perception of Age instrument, which assesses age of appearance relative to actual age.

Results

The BoNTA topical cream (CosmeTox) treatment produced significant improvements in the Facial Lines Outcome scores, which were maintained throughout the study period and lasted more than 3 months. The BoNTA topical cream treatment also reduced the age of appearance for a majority of subjects. The placebo had no effect on any measure. No serious adverse events occurred during the entire study period.

Conclusion

Topical treatment with the stabilized BoNTA cream (CosmeTox) to the entire upper facial lines resulted in significantly improved facial features and age appearance, as measured by the subjects and clinicians. The BoNTA cream (CosmeTox) resulted in a significantly younger, more satisfying, relaxed appearance.

Keywords

Aesthetics medicine Botulinum toxin-A (BoNTA) BoNTA-topical cream CosmeTox Facial lines Mouth Neck 

References

  1. 1.
    Carruthers A, Carruthers J (1998) History of the cosmetic use of botulinum A exotoxin. Dermatol Surg 24:1168–1170PubMedCrossRefGoogle Scholar
  2. 2.
    Carruthers J, Carruthers A (1998) The adjunctive usage of botulinum toxin. Dermatol Surg 24:1244–1247PubMedCrossRefGoogle Scholar
  3. 3.
    Heckmann M, Teichmann B, Schroder U et al (2003) Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. J Am Acad Dermatol 49:213–216PubMedCrossRefGoogle Scholar
  4. 4.
    Finn JC, Cox SE, Earl ML (2003) Social implications of hyperfunctional facial lines. Dermatol Surg 29:450–455CrossRefGoogle Scholar
  5. 5.
    Carruthers J, Fagien S, Matarasso SL, Botox Consensus Group (2004) Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 114(Suppl):1S–22SPubMedCrossRefGoogle Scholar
  6. 6.
    Fagien S (2003) Botulinum toxin type A for facial aesthetic enhancement: role in facial shaping. Plast Reconstr Surg 112(Suppl):6S–18SPubMedCrossRefGoogle Scholar
  7. 7.
    Carruthers JA, Lowe NJ, Menter MA et al (2002) A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 46:840–849PubMedCrossRefGoogle Scholar
  8. 8.
    Carruthers A, Carruthers J, Cohen J (2003) A prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in female subjects with horizontal forehead rhytides. Dermatol Surg 29:461–467PubMedCrossRefGoogle Scholar
  9. 9.
    Carruthers A, Carruthers J (2007) Foreword to special issue on botulinum toxin. Dermatol Surg 33:S1–S1CrossRefGoogle Scholar
  10. 10.
    Carruthers A, Carruthers J (2007) Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes. Dermatol Surg 33:S10–S17PubMedCrossRefGoogle Scholar
  11. 11.
    Fagian D, Cox SA, Finn J, Werscheller W, Kowalski J (2007) Patient-reported outcomes with botulinum toxin Type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg 33:S2–S9CrossRefGoogle Scholar
  12. 12.
    Rzanzy B, Dill-Muller D, Grablowicz D, Heckmann M, Caird D (2007) On behalf of the German–Austrian Retrospective Study Group, repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg 33:S18–S25CrossRefGoogle Scholar
  13. 13.
    Singh G, Kelly M (2003) Botox an “elixir of youth”? Eur J Plast Surg 26:273–4CrossRefGoogle Scholar
  14. 14.
    Markey AC (2000) Botulinum A exotoxin in cosmetic dermatology. Clin Exp Dermatol 25:173–175PubMedCrossRefGoogle Scholar
  15. 15.
    Carruthers A, Carruthers J (1998) Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg 24:1189–1194PubMedCrossRefGoogle Scholar
  16. 16.
    Garcia A, Fulton JE Jr (1996) Cosmetic denervation of the muscles of facial expression with botulinum toxin: a dose–response study. Dermatol Surg 22:39–43PubMedCrossRefGoogle Scholar
  17. 17.
    Benedetto AV (1999) The costmetic uses of botulinum toxin type A. Int J Dermatol 38:641–655PubMedCrossRefGoogle Scholar
  18. 18.
    Carruthers A, Carruthers J, Lowe NJ et al (2004) One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res 7:1–20Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Cirugia Plastica EsteticaCentro Medico BarrancasBuenos AiresArgentina
  2. 2.DPM Therapeutics CorporationAncasterCanada

Personalised recommendations